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We report a substantial and sustained reduction in norovirus outbreak and norovirus-positive 
laboratory reports to Public Health England (PHE) since SARS-CoV-2 (COVID-19) control 
measures were first introduced in 2020. This has raised concerns around the direct and 
indirect effects of the pandemic on routine surveillance functions, and the need to consider 
the potential risk of unusual disease activity and novel norovirus strain emergences when 
such interventions are relaxed.  
 
The observed decrease in norovirus reporting (≥84.6%, Figure 1) throughout 2020 across all 
four national surveillance systems used to monitor norovirus activity [1], and the marked 
decline in referral of norovirus-positive samples for genotyping and monitoring diversity of 
circulating norovirus strains [1, 2] have limited our ability to perform effective surveillance. 
These metrics were critical in detecting emerging epidemics during previous norovirus strain 
replacement events, such as temporally unusual levels of activity seen in the UK during the 
2002 summer preceding the 2002/2003 pandemic event [3], or significant changes in the 
virus genome in the absence of an observed cumulative increase in confirmed norovirus 
laboratory reports, as was associated with emergence of the GII.4/Sydney strain in England 
in 2012 [2].  
 
Globally, norovirus strain replacement events over the last 20 years have occurred every 3-4 
years [4], with the last recorded in the UK in 2012[2, 4]. Therefore, it is crucial that molecular 
surveillance is prioritised in 2021, specifically referral of norovirus-positive samples to the 
national reference laboratory for molecular characterisation to maximise the opportunity for 
timely detection of novel noroviruses which could lead to a strain replacement event. 
Consequently, PHE has updated referral guidance for PHE Regional Public Health and 
Collaborating Laboratories to include norovirus-positive samples from sporadic cases and 
outbreak-associated samples in both healthcare and community settings, aiming to highlight 
the importance of ongoing surveillance and improve the size and representativeness of 
molecular surveillance.  
 
Changes in healthcare seeking behaviour, disruption to service provision and operational 
changes in local capacity to detect, test and report norovirus cases or outbreaks due to the 
COVID-19 pandemic has adversely impacted on norovirus surveillance. However, the 
reasons for the observed decrease in norovirus reporting are considered multifactorial and 
the non-pharmaceutical interventions (NPIs) introduced to reduce COVID-19 transmission in 
England have almost certainly resulted in a true decrease in norovirus transmission; raising 
the question of what may happen when measures are relaxed.   
 
Similar reductions in norovirus reporting have been observed in other countries including 
Germany , USA  and Australia [1, 5] following implementation of COVID-19 control 
measures [6]. Furthermore, unusual, delayed temporal peaks in disease activity following 
relaxation of NPI’s have been reported for respiratory syncytial virus in the past [5, 7] and 
similar disease dynamics may be expected for norovirus whose transmission is facilitated by 
close social contact. Recent data from Australia support this, where relaxation of COVID-19 
NPIs coincided with a sudden increase in gastroenteritis outbreaks in childcare settings 












Therefore, anticipating the imminent easing of COVID-19 control measures, we believe there 
is a real risk of a sudden and rapid increase in norovirus transmission which would result in 
temporally unusual activity due to:  
• an increase in behaviours which facilitate transmission; 
• an increased number of susceptible individuals in the population due to low norovirus 
activity throughout 2020; 
• rapid emergence of a norovirus strain with epidemic potential; 
• or most likely, a combination of these factors.  
 
Increased or unusual norovirus activity has the potential to overwhelm NHS services [8, 9], 
especially following the prolonged period of pressure experienced during the COVID-19 
pandemic and the substantial number of people awaiting postponed, non-urgent treatments 
[10]. The paucity of surveillance data on norovirus activity and circulating strains in England 
during the 2020/2021 winter season means key indicators of a potential strain replacement 
event are not being monitored as effectively as prior to the emergence of COVID-19 and 
could leave frontline services insufficiently prepared for any increased ‘out-of-season’ 
norovirus activity. Therefore, reporting of outbreaks and submission of norovirus-positive 
samples to the national reference laboratory is essential to maximise the opportunity to 
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Figure title: Figure 1. Decline in norovirus laboratory reports in England (A) and suspected 
and confirmed norovirus outbreak reports in England by setting (B), 2019/2020 season and 
weeks 27 to 52 of 2020/2021 season compared to the five-season mean with 95% 
confidence intervals. 
Figure footnotes:  Data are reported by epidemiological seasons running from week 27 in 
the first year to week 26 in the second year, capturing the winter peak of activity in one 
reporting period. Five-season mean and 95% confidence intervals for 2019/20 and 2020/21 
seasons are calculated from the 5- season periods of 2014/15 to 2018/19, and 2015/16 to 
2019/20, respectively.  
Since the first national lockdown in March 2020, multiple areas in England have been 
subject to variable levels of coronavirus restrictions at the regional level, with a national level 
3-tiered restrictions approach first formally implemented in England in October 2020. 




















































11th March: WHO declares SARS-CoV-2 a 
23rd March: Start of first lockdown in England
(14 week duration)












































11th Mar: WHO declares SARS-CoV-2 a pandemic
5th Nov: start of second lockdown in England
(4 week duration)
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